Selecta Biosciences (SELB) Receiving Somewhat Positive Media Coverage, Study Finds

Press coverage about Selecta Biosciences (NASDAQ:SELB) has trended somewhat positive on Saturday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Selecta Biosciences earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the company an impact score of 44.6239452018431 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Selecta Biosciences (NASDAQ:SELB) traded down $0.01 during mid-day trading on Friday, hitting $8.50. The stock had a trading volume of 163,330 shares, compared to its average volume of 289,067. The company has a quick ratio of 9.48, a current ratio of 9.48 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $189.64 and a price-to-earnings ratio of -2.74. Selecta Biosciences has a fifty-two week low of $7.95 and a fifty-two week high of $24.02.

A number of brokerages have recently weighed in on SELB. Zacks Investment Research lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. ValuEngine lowered Selecta Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Canaccord Genuity reissued a “buy” rating and issued a $30.00 price objective on shares of Selecta Biosciences in a report on Thursday, January 18th. Finally, UBS Group lowered Selecta Biosciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Selecta Biosciences currently has a consensus rating of “Hold” and a consensus target price of $23.50.

WARNING: This news story was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/02/17/selecta-biosciences-selb-receiving-somewhat-positive-media-coverage-study-finds.html.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Insider Buying and Selling by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply